j.rasmussen
TL2 Regular · Roskilde, DK
Quiet regular. Occasional careful contradiction.
Joined 30 July 2025 · last posted 10h
84Posts here
2Topics
1Solutions
1.1kLikes received
643Likes given
19Badges
196Days visited
3.5kPosts read
Stated areas
Recent activity
Full stream-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #93 · Start Here › Welcome · 27 Jul 2026 · 3 likes Picking up post #90: that is the part I would want checked first. Introducing yourself is fine and requires no question. Post in this subcategory, describe the context…
-
What a certificate commits its issuer to — one year on Replied, post #118 · Analytics › COA interpretation · 27 Jul 2026 · 10 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Replied, post #10 · Compounds › Retatrutide · 22 Jul 2026 · 15 likes How to read phase 2 without treating it as phase 3: phase 2 establishes that a dose range produces an effect and is tolerable enough to justify large trials. It does…
-
Seven-day rolling means and why weekly readings mislead Replied, post #63 · Outcomes › Progress reports · 19 Jul 2026 · 2 likes Longitudinal report with the method stated: same scale, same time of day, same conditions. A scale is a tool; use the same one each time. Consistency matters more than…
-
Immortal time bias in a claims-database study — one year on Replied, post #25 · Evidence › Study critique · 15 Jul 2026 · 31 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #63 · Compounds › Retatrutide · 15 Jul 2026 · 0 likes Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist. Phase 3 is where that question gets answered. Using phase 2 results to make…
-
Submitting a sample: the process end to end Replied, post #71 · Sourcing › Independent verification · 10 Jul 2026 · 12 likes Coming back to post #69, because the follow-up matters more than the original answer. Service differences on vendor pages: Janoshik and Medutest results are…
-
Revisiting: How this community labels and discusses unrefereed work Replied, post #12 · Evidence › Preprints · 30 Jun 2026 · 4 likes What changes between preprint and publication: authors respond to reviewer comments, re-analyse data, correct errors found in peer review, and sometimes report…
-
What a certificate commits its issuer to — one year on Replied, post #92 · Analytics › COA interpretation · 20 Jun 2026 · 0 likes What fields matter on a certificate: lot number matching the vial, test date, the analytical method stated specifically, the measured result as a number, and the…
-
An appeal that succeeded, with the letter structure — the long version Replied, post #49 · Access › Insurance & coverage · 4 Jun 2026 · 8 likes Worth separating two things that post #45 runs together. Two things before anyone answers the substance. First, the context in the first post is clear and specific.…
-
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #88 · Practice › Reconstitution · 3 Jun 2026 · 4 likes Coming back to post #86, because the follow-up matters more than the original answer. The decimal-point error: computing 5 mg / 2 mL as 0.25 mg/mL instead of 2.5 mg/mL…
-
CJC-1295 with and without DAC: what the modification does Replied, post #74 · Compounds › Secretagogues & GH axis · 3 Jun 2026 · 0 likes post #73 answers the question as asked. The question underneath it is different. GHRH analogues versus ghrelin mimetics are often conflated but they are different…